Cytokinetics, Inc. (CYTK) Tops Q1 EPS by 1c

Cytokinetics, Inc. (NASDAQ: CYTK) reported Q1 EPS of ($0.13), $0.01 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $1.82 million versus the consensus estimate of $1.06 million.

For earnings history and earnings-related data on Cytokinetics, Inc. (CYTK) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Birchtech Corp. (BCHT) Misses Q2 EPS by 7c
• 4D Molecular Therapeutics, Inc. (FDMT) Misses Q2 EPS by 3c